Healthpeak Properties, Inc.

Healthpeak Properties, Inc. (DOC) Market Cap

Healthpeak Properties, Inc. has a market capitalization of $11.89B.

Financials based on reported quarter end 2025-12-31

Price: $17.10

-0.27 (-1.55%)

Market Cap: 11.89B

NYSE · time unavailable

CEO: Scott Brinker

Sector: Real Estate

Industry: REIT - Healthcare Facilities

IPO Date: 1985-05-23

Website: https://www.healthpeak.com

Healthpeak Properties, Inc. (DOC) - Company Information

Market Cap: 11.89B · Sector: Real Estate

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery.

Analyst Sentiment

68%
Buy

Based on 40 ratings

Analyst 1Y Forecast: $19.18

Average target (based on 3 sources)

Consensus Price Target

Low

$17

Median

$17

High

$21

Average

$18

Potential Upside: 4.3%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 Healthpeak Properties, Inc. (DOC) — Investment Overview

🧩 Business Model Overview

Healthpeak Properties, Inc. (trading as DOC) is a real estate investment trust (REIT) specializing in healthcare-related properties across the United States. The company’s strategic focus is on owning, developing, and managing high-quality real estate assets that cater primarily to the medical office, life science, and senior housing sectors. Its tenant base is composed largely of healthcare providers, research organizations, and senior living operators, allowing Healthpeak to derive stable rental income and long-term occupancy commitments. The company’s operating domains are concentrated in major metropolitan and innovation-driven markets with strong demographic tailwinds and robust healthcare infrastructure.

💰 Revenue Model & Ecosystem

Healthpeak generates revenue through long-term leasing arrangements with a diversified mix of tenants in its property portfolio. Revenue streams are primarily derived from rental income but are supplemented by ancillary services such as property management and development fees. The company’s business model emphasizes high-occupancy assets with creditworthy tenants, offering resilience through healthcare’s non-cyclical demand profile. In addition to direct property ownership, Healthpeak often collaborates with healthcare systems and operators, creating a symbiotic ecosystem where real estate expertise supports healthcare service delivery.

🧠 Competitive Advantages

  • Brand strength: Healthpeak is recognized as a leading healthcare REIT, benefitting from longstanding relationships with blue-chip healthcare providers and operators.
  • Switching costs: Relocating major healthcare services or research facilities is costly and complex, fostering tenant stickiness and long-term lease agreements.
  • Ecosystem stickiness: The integration of property services and close alignment with healthcare delivery enhances tenant loyalty and value creation beyond standard landlord-tenant dynamics.
  • Scale + supply chain leverage: Healthpeak’s national footprint and significant balance sheet offer economies of scale in procurement, development, and property management.

🚀 Growth Drivers Ahead

Healthcare real estate benefits from enduring demographic trends, including an aging population and heightened demand for outpatient services. Healthpeak is strategically positioned to capitalize on these tailwinds through targeted investments in high-growth regions and medical research hubs. Portfolio optimization—divesting non-core assets and reinvesting in life science or medical office properties—supports ongoing value creation. Partnerships with leading health systems and national operators enable Healthpeak to expand its footprint and capture emerging demand sectors such as biotechnology labs and ambulatory care facilities. Additionally, operational efficiencies, value-added redevelopments, and leveraging technological innovation within facilities represent ongoing avenues for growth.

⚠ Risk Factors to Monitor

Investors should be aware of competitive dynamics within the healthcare REIT space, including potential oversupply in select markets or tenant consolidation leading to bargaining power shifts. The sector faces heightened regulatory scrutiny tied to healthcare reimbursement and operational standards, which could indirectly impact property profitability. Cost inflation, interest rate fluctuations, and challenges related to property redevelopment or occupancy transitions represent additional sources of margin pressure. Moreover, disruptions in the healthcare delivery model, evolving patient preferences, and the potential for new entrants adopting alternative property use models could present longer-term risks.

📊 Valuation Perspective

Market participants often value Healthpeak relative to other publicly traded healthcare REITs, considering factors such as asset quality, tenant diversification, and geographic exposure. Premiums or discounts versus peers are typically influenced by the stability of cash flows, perceived growth trajectory, and portfolio resilience during economic cycles. Properties in innovation clusters or with higher exposure to life science assets may command more favorable market multiples, while portfolios heavily weighted to senior housing or transitional care may be viewed with increased scrutiny.

🔍 Investment Takeaway

Healthpeak Properties presents a compelling investment thesis built on the resilience of healthcare real estate, a focus on high-barrier markets, and strategic alignment with sector growth drivers. Bulls may point to its reputation, operator relationships, and diversified asset mix as sources of durable competitive advantage. However, risks relating to shifts in healthcare demand, regulatory headwinds, and changing real estate dynamics warrant caution. A balanced perspective acknowledges Healthpeak’s strengths as a sector leader, while recognizing its exposure to evolving trends in healthcare delivery and property use.


⚠ AI-generated research summary — not financial advice. Validate using official filings & independent analysis.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"DOC reported revenue of $719 million for the quarter ending December 2025, with a net income of $114 million, leading to an EPS of $0.16. Currently, the company has a net margin of 15.84%. Despite no specific free cash flow data available, DOC maintains a strong balance sheet with total assets of $20.34 billion and net cash position reflected by a negative net debt of $467 million. Over the last year, DOC has consistently paid a quarterly dividend of $0.10167. The company's 1-year stock performance concludes with a consensus target price of $18.71. Growth has been stable. Profit margins indicate operational efficiency and prudent expense management. Cash flow metrics need attention as comprehensive data is absent; however, dividends reflect liquidity and commitment to returns. Net debt is negative, showcasing financial health and capacity to manage obligations. Valuation appears modest against forward-looking consensus, supported by analyst sentiment. Shareholder returns have been favorable through steady dividends."

Revenue Growth

Neutral

Growth appears steady with sustainable revenue streams; further diversification may enhance stability.

Profitability

Good

Strong net margins and EPS growth indicate robust profitability and efficient operations.

Cash Flow Quality

Fair

Cash flow specifics are lacking, but regular dividends suggest adequate liquidity management.

Leverage & Balance Sheet

Strong

The balance sheet is very strong, marked by a negative net debt position, indicating financial resilience.

Shareholder Returns

Good

Shareholders benefit from consistent quarterly dividends, reflecting solid value creation.

Analyst Sentiment & Valuation

Neutral

Valuation metrics suggest a fair market position with a reasonable analyst consensus.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Healthpeak (DOC) delivered FY2025 results roughly in line with guidance, driven by strong outpatient and senior housing performance, while life science remained a drag. Management is recycling capital from stabilized outpatient assets into strategic opportunities like the Gateway campus and advancing the Janus Living IPO to crystallize value from senior housing. 2026 guidance reflects near-term lab headwinds and higher financing costs, but the company highlights early signs of a life science recovery, robust outpatient fundamentals, and strong senior housing momentum, positioning the portfolio for improved growth beyond 2026.

Growth

  • Total portfolio same-store cash NOI grew 3.9% in Q4 and 4.0% for FY2025
  • Outpatient medical same-store growth: 3.9% FY2025; record 4.9M sf of leasing (1.0M sf new), 5% cash renewal spreads, 79% retention, 91% occupancy
  • Lab same-store growth: 1.5% FY2025; 77% total occupancy (Gateway depressed by >150 bps); ~1.5M sf leasing (562k sf new), 5% cash renewal spreads
  • Senior housing same-store growth: 12.6% FY2025, including 16.7% in Q4; record entrance fee sales

Business Development

  • Acquired ~1.4M sf Gateway lab campus in South San Francisco; campus has >500k sf vacancy for upside
  • Now own/control ~210 acres (~one-third of submarket land) and ~6.5M sf in South San Francisco
  • Sold $325M of fully stabilized outpatient assets in Q4 at a low-6% cap rate
  • Forming Janus Living (pure-play senior housing REIT); Healthpeak to contribute entire senior housing portfolio, receive shares, then IPO (RIDEA structure); Healthpeak to manage and remain a significant shareholder
  • Closed $314M buyout of JV partner’s 46.5% interest in 3,400-unit senior housing portfolio (19 communities); transitioning 11 to Pegasus and 8 to CL Senior Living
  • Additional $360M of newer-vintage senior housing acquisitions under LOI/PA (Orlando, North Atlanta) expected to close in Q1 2026 and be contributed to Janus Living
  • 2026 YTD acquisitions: $464M (includes the $314M senior housing JV buyout and remaining Gateway interests)

Financials

  • Q4 2025 FFO as adjusted: $0.47/sh; AFFO: $0.40/sh; total same-store cash NOI: +3.9%
  • FY2025 FFO as adjusted: $1.84/sh; AFFO: $1.69/sh; total same-store cash NOI: +4.0%
  • Net debt to adjusted EBITDA: 5.2x; liquidity: $2.4B
  • 2026 guidance: FFO as adjusted $1.70–$1.74/sh; total same-store NOI -1% to +1% (Outpatient +2% to +3%; Lab -5% to -10%; Senior housing +8% to +12%)
  • Earnings headwind in 2026 primarily from lab occupancy loss (~$0.12/sh impact), including a $68M contractual purchase option in Salt Lake City at an ~11% cap rate and drag from higher-rate refinancing, a ~$150M 2025 loan at ~10%, and redevelopment

Capital & Funding

  • Active capital recycling plan targeting $1B+ of asset sales/recaps/loan repayments in 2026; leveraging strong private market demand for outpatient assets
  • $1.1B of 2026 debt maturities: $650M senior unsecured notes (July) and ~$440M secured mortgages to be refinanced or repaid
  • Maintaining balance sheet discipline to fund strategic investments and portfolio growth
  • Janus Living IPO filed confidentially (S-11 in December); expected to close in 1H26; no material impact assumed in 2026 guidance

Operations & Strategy

  • Merger with Physicians Realty Trust yielded ~$70M synergies and enabled internalized property management across outpatient and life science
  • Corporate automation and investment management scaling; hired Head of Enterprise Innovation (Omkar Joshi) to drive efficiency
  • Paused life science capital deployment during downturn; now selectively acquiring at compelling bases (e.g., Gateway) and positioning for recovery
  • Outpatient platform focus on health system relationships; low new supply and favorable policy shifts support sustained performance
  • Senior housing operator transitions to Pegasus and CL to enhance execution; Healthpeak to manage Janus Living post-IPO for aligned incentives
  • Added market leaders for life science (Dennis Sullivan in San Diego; Claire Brown in Boston) and SVP Finance/IR for Janus Living (Jonathan Hughes)

Market & Outlook

  • Outpatient benefiting from shift to lower-cost settings and supportive CMS policies; private market cap rates compressing; new construction remains low
  • Life science showing early signs of recovery with improved capital raising/M&A; new deliveries expected to go to zero for several years; some supply repurposing
  • Bay Area led 2025 life science absorption/leasing; strongest current tenant demand; internal pipeline weighted to new leasing
  • Expect lab occupancy to improve by YE 2026, though earnings recovery will lag due to lease-up timing
  • Senior housing fundamentals remain favorable; management expects another strong growth year in 2026

Risks Or Headwinds

  • Life science occupancy and earnings pressure; lease-up timing and large, lumpy deal cadence can drive quarterly volatility
  • Dependence on sustained capital markets recovery for life science tenant funding and leasing
  • Higher refinancing costs in 2026 and drag from redevelopment projects
  • Execution risk around Janus Living IPO (market conditions, SEC timing) and operator transitions
  • Reliance on asset sales/recaps to fund investments amid changing private market conditions

Sentiment: MIXED

Note: This summary was synthesized by AI from the DOC Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (DOC)

© 2026 Stock Market Info — Healthpeak Properties, Inc. (DOC) Financial Profile